![Jim Kastenmayer](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jim Kastenmayer
Consejero General en ARRIVENT BIOPHARMA, INC. .
Fortuna: 143 362 $ al 31/05/2024
Cargos activos de Jim Kastenmayer
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
ARRIVENT BIOPHARMA, INC. | Consejero General | 01/09/2023 | - |
Secretario Corporativo | 01/09/2023 | - |
Historial de carrera de Jim Kastenmayer
Antiguos cargos conocidos de Jim Kastenmayer.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
SPYRE THERAPEUTICS, INC. | Director Ejecutivo | 24/08/2022 | 29/11/2022 |
Consejero General | 15/07/2021 | 16/05/2023 | |
Presidente | 24/08/2022 | 29/11/2022 | |
Secretario Corporativo | 29/11/2022 | 16/05/2023 | |
VIELA BIO, INC. | Consejero General | 01/01/2020 | 01/03/2021 |
Secretario Corporativo | 01/01/2020 | 01/03/2021 | |
ASTRAZENECA PLC | Consejero General | 01/05/2012 | 01/12/2019 |
Medimmune, Inc. | Corporate Officer/Principal | - | - |
Formación de Jim Kastenmayer.
Georgetown University Law Center | Graduate Degree |
Michigan State University | Doctorate Degree |
University of Virginia | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 8 |
Reino Unido | 2 |
Operativa
General Counsel | 4 |
Corporate Secretary | 3 |
Graduate Degree | 1 |
Sectorial
Health Technology | 6 |
Consumer Services | 4 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
ASTRAZENECA PLC | Health Technology |
SPYRE THERAPEUTICS, INC. | Health Technology |
ARRIVENT BIOPHARMA, INC. | Health Technology |
Empresas privadas | 2 |
---|---|
Viela Bio, Inc.
![]() Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
Medimmune, Inc. | Health Technology |
- Bolsa de valores
- Insiders
- Jim Kastenmayer
- Experiencia